Presentations Include 12-Month Outcomes from the SELUTION4ISR Trial and the SELUTION DeNovo Trial in Coronary Lesions, Alongside Analyses on How Procedural Experience Influences Treatment Strategy ...

SELUTION DeNovo Trial - the largest randomized Drug Eluting Balloon trial - demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions.

SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% primary ...

NYON, Switzerland, Nov. 24, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in the ISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the ...

GENEVA, Jan. 10, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal ...

Cordis Corp. covered its bets a bit as it closed the acquisition of M.A. Med Alliance SA (Medalliance) announced almost a year ago. While the total payment for the company could total $1.135 billion, ...

GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent ...

The MarketWatch News Department was not involved in the creation of this content. Presentations Include 12-Month Outcomes from the SELUTION4ISR Trial and the SELUTION DeNovo Trial in Coronary Lesions, ...